Association between pharmacotherapy and secondary vertebral fracture managed with a brace in a real-world setting: A nationwide database study in Japan.
denosumab
osteoporosis
pharmacotherapy
secondary fracture
vertebral fracture
Journal
Geriatrics & gerontology international
ISSN: 1447-0594
Titre abrégé: Geriatr Gerontol Int
Pays: Japan
ID NLM: 101135738
Informations de publication
Date de publication:
12 Mar 2024
12 Mar 2024
Historique:
revised:
09
02
2024
received:
21
06
2023
accepted:
21
02
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
aheadofprint
Résumé
This retrospective cohort study assessed the association between the incidence of secondary vertebral fracture managed with a brace (SVF) and pharmacotherapy. The association between the incidence of SVF and the presence, type, and medication possession ratio (MPR) of pharmacotherapy was investigated using medical insurance data acquired from the National Database of Health Insurance Claims and Specific Health Checkups of Japan. The data of female patients (n = 637 303) were analyzed. The 2-year incidence of SVF was 73.5 per 10 000 patients (n = 4687). Approximately 0.73% of patients without medications and 0.74% with medications had SVF. Patients taking bisphosphonates (0.87), denosumab (0.77), and selective estrogen receptor modulators (0.88) had significantly lower standardized incidence ratios (SIRs) than patients not taking medications after the occurrence of primary fracture; meanwhile, patients taking parathyroid hormone medications had considerably higher SIRs than those not taking medications. The non-SVF group (59.1%) had a significantly higher mean MPR than the SVF group (55.5%). Patients taking denosumab in the non-SVF group (68.2%) had the highest mean MPR. The proportion of patients taking denosumab with an MPR of ≥80% in the non-SVF group was significantly higher than that in the SVF group. Patients taking medications were at a lower risk of developing SVF than those not taking medications. Although this study did not compare the medications' SVF prevention effects, patients taking denosumab had a 0.77 SIR of SVF in Japan. The effect of pharmacotherapy on SVF prevention might be affected by the MPR of each medication. Geriatr Gerontol Int 2024; ••: ••-••.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : 28th Pfizer Health Research Grant, 52nd (2019) Medical Research Grant from Taijyu Life Welfare Foundation, and 2020 Research Grant from Japan Osteoporosis Foundation
Informations de copyright
© 2024 Japan Geriatrics Society.
Références
Iihara N, Ohara E, Bando Y, Yoshida T, Ohara M, Kirino Y. Fragility fractures in older people in Japan based on the national health insurance claims database. Biol Pharm Bull 2019; 42: 778-785.
Lems WF, Paccou J, Zhang J et al. Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services. Osteoporos Int 2021; 32: 399-411.
Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int 2000; 11: 556-561.
Dionyssiotis Y. Management of osteoporotic vertebral fractures. Int J Gen Med 2010; 3: 167-171.
Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15: 721-739.
Frederiksen A, Abrahamsen B, Johansen PB, Sørensen HA. Danish, national cross-sectional observational study on the prevalence of prior major osteoporotic fractures in adults presenting with hip fracture-limitations and scope for fracture liaison services in prevention of hip fracture. Osteoporos Int 2018; 29: 109-114.
Banefelt J, Åkesson KE, Spångéus A et al. Risk of imminent fracture following a previous fracture in a Swedish database study. Osteoporos Int 2019; 30: 601-609.
Li CC, Hsu JC, Liang FW, Chang YF, Chiu CJ, Wu CH. The association between osteoporosis medications and lowered all-cause mortality after hip or vertebral fracture in older and oldest-old adults: a nationwide population-based study. Aging 2022; 14: 2239-2251.
Hadji P, Schweikert B, Kloppmann E et al. Osteoporotic fractures and subsequent fractures: imminent fracture risk from an analysis of German real-world claims data. Arch Gynecol Obstet 2021; 304: 703-712.
Soen S, Fukunaga M, Sugimoto T et al. Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 2013; 31: 247-257.
Japan Osteoporosis Society. Guidelines on the prevention and treatment of osteoporosis 2015. The committee for development of the guidelines on the prevention and treatment of osteoporosis. 2015 (in Japanese) [Cited 15 April 2023]. Available from: http://www.josteo.com/ja/guideline/doc/15_1.pdf.
Nakatoh S, Fujimori K, Ishii S et al. Insufficient increase in bone mineral density testing rates and pharmacotherapy after hip and vertebral fracture: analysis of the national database of health insurance claims and specific health checkups of Japan. Arch Osteoporos 2021; 16: 130.
Chen YC, Lin WC. Poor 1st-year adherence to anti-osteoporotic therapy increases the risk of mortality in patients with magnetic resonance imaging-proven acute osteoporotic vertebral fractures. Patient Prefer Adherence 2017; 11: 839-843.
Kanis JA, Cooper C, Hiligsmann M, Rabenda V, Reginster JY, Rizzoli R. Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int 2011; 22: 2565-2573.
Nakatoh S, Fujimori K, Ishii S et al. Insufficient persistence to pharmacotherapy in Japanese patients with osteoporosis: an analysis of the national database of health insurance claims and specific health checkups in Japan. Arch Osteoporos 2021; 16: 131.
Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114: 919-923.
Lindsay R, Silverman SL, Cooper C et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320-323.
Briggs AM, Greig AM, Wark JD. The vertebral fracture cascade in osteoporosis: a review of aetiopathogenesis. Osteoporos Int 2007; 18: 575-584.
Che H, Breuil V, Cortet B et al. Vertebral fractures cascade: potential causes and risk factors. Osteoporos Int 2019; 30: 555-563.
Broy SB. The vertebral fracture cascade: etiology and clinical implications. J Clin Densitom 2016; 19: 29-34.
Jacobs E, Senden R, McCrum C, van Rhijn LW, Meijer K, Willems PC. Effect of a semirigid thoracolumbar orthosis on gait and sagittal alignment in patients with an osteoporotic vertebral compression fracture. Clin Interv Aging 2019; 14: 671-680.
Meccariello L, Muzii VF, Falzarano G et al. Dynamic corset versus three-point brace in the treatment of osteoporotic compression fractures of the thoracic and lumbar spine: a prospective, comparative study. Aging Clin Exp Res 2017; 29: 443-449.
Li M, Law SW, Cheng J, Kee HM, Wong MS. A comparison study on the efficacy of SpinoMed® and soft lumbar orthosis for osteoporotic vertebral fracture. Prosthet Orthot Int 2015; 39: 270-276.
Pfeifer M, Kohlwey L, Begerow B, Minne HW. Effects of two newly developed spinal orthoses on trunk muscle strength, posture, and quality-of-life in women with postmenopausal osteoporosis: a randomized trial. Am J Phys Med Rehabil 2011; 90: 805-815.
Diacinti D, Guglielmi G. How to define an osteoporotic vertebral fracture? Quant Imaging Med Surg 2019; 9: 1485-1494.
Fink HA, Milavetz DL, Palermo L et al. What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res 2005; 20: 1216-1222.
Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ 3rd. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 1992; 7: 221-227.
Kanis JA, Cooper C, Rizzoli R, Reginster JY. Scientific advisory Board of the European Society for clinical and economic aspects of osteoporosis (ESCEO) and the committees of scientific advisors and National Societies of the international osteoporosis foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2019; 30: 3-44.
Prost S, Pesenti S, Fuentes S, Tropiano P, Blondel B. Treatment of osteoporotic vertebral fractures. Orthop Traumatol Surg Res 2021; 107: 102779.
Luthman S, Widén J, Borgström F. Appropriateness criteria for treatment of osteoporotic vertebral compression fractures. Osteoporos Int 2018; 29: 793-804.
Bastounis A, Langley T, Davis S et al. Assessing the effectiveness of bisphosphonates for the prevention of fragility fractures: an updated systematic review and network meta-analyses. JBMR Plus 2022; 6: e10620.
Wei FL, Gao QY, Zhu KL et al. Efficacy and safety of pharmacologic therapies for prevention of osteoporotic vertebral fractures in postmenopausal women. Heliyon 2022; 9: e11880.
Ministry of Health, Labour, and Welfare. The Popularization and State of Electronic Receipt Claims. Tokyo: Ministry of Health, Labour, and Welfare; 2020 (in Japanese) [Cited 15 April 2023]. Available from: https://www.mhlw.go.jp/file/06-Seisakujouhou-12400000-Hokenkyoku/0000099002.pdf.
Siris ES, Harris ST, Rosen CJ et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81: 1013-1022.
Ferrari S, Langdahl B. Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. Nat Rev Rheumatol 2023; 19: 307-317.
Jin YZ, Lee JH, Xu B, Cho M. Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials. BMC Musculoskelet Disord 2019; 20: 399.
Nakatoh S, Fujimori K, Ishii S et al. Association of pharmacotherapy with the second hip fracture incidence in women: a retrospective analysis of the national database of health insurance claims and specific health checkups of Japan. Geriatr Gerontol Int 2022; 22: 930-937.
Conley RB, Adib G, Adler RA et al. Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition. J Bone Miner Res 2020; 35: 36-52.
Langdahl BL, Rajzbaum G, Jakob F et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo observational study (EFOS). Calcif Tissue Int 2009; 85: 484-493.
Kyvernitakis I, Kostev K, Kurth A, Albert US, Hadji P. Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider. Osteoporos Int 2014; 25: 2721-2728.
Sato M, Tsujimoto M, Kajimoto K, Uetake H, Shimoda H, Fujiwara S. Effect of a patient-support program on once-daily teriparatide adherence and persistence in the Japan fracture observational study (JFOS). Arch Osteoporos 2018; 13: 74.